Attached files
| file | filename |
|---|---|
| EX-99.1 - EX-99.1 - Anacor Pharmaceuticals, Inc. | a13-8128_1ex99d1.htm |
| EX-99.2 - EX-99.2 - Anacor Pharmaceuticals, Inc. | a13-8128_1ex99d2.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): March 21, 2013
ANACOR PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
|
DELAWARE |
|
001-34973 |
|
25-1854385 |
|
(State of incorporation) |
|
(Commission File No.) |
|
(IRS Employer Identification No.) |
1020 East Meadow Circle
Palo Alto, CA 94303-4230
(Address of principal executive offices and zip code)
Registrant’s telephone number, including area code: (650) 543-7500
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
ITEM 8.01 OTHER EVENTS.
On March 21, 2013, Anacor Pharmaceuticals, Inc. issued a press release announcing results from a Phase 2 clinical trial of AN2728 for the treatment of adolescents with atopic dermatitis and hosted a conference call to discuss the results.
Copies of such press release and supplemental slides in connection with this conference call are attached as Exhibits 99.1 and 99.2, respectively, and are incorporated herein by reference.
ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS.
(d) Exhibits.
|
Exhibit Number |
|
Description |
|
99.1 |
|
Press Release titled “Anacor Pharmaceuticals Announces Positive Results From Phase 2 Dose-Ranging Study of AN2728 in Adolescents with Atopic Dermatitis” dated March 21, 2013 |
|
99.2 |
|
Anacor Pharmaceuticals, Inc. Conference Call Slides March 21, 2013 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
Date: March 21, 2013 |
ANACOR PHARMACEUTICALS, INC. | |
|
|
|
|
|
|
By: |
/s/ Geoffrey M. Parker |
|
|
|
Geoffrey M. Parker |
|
|
|
Senior Vice President, Chief Financial Officer |